| Name | Title | Contact Details |
|---|
Creative Bus Sales is now Model 1 Commercial Vehicles. Nothing about passion or our leadership has changed, and our brand represents the creativity, expertise, and vision we put to work for customers across the U.S. As the largest bus and commercial transit dealership in the U.S., Model 1 is at the forefront of solving commercial and community transportation issues with visionary thinking – including not just vehicles but also distribution, parts, service, F&I, and more. Strong partnerships with more than 20 top manufacturers, the largest in-stock vehicle inventory in the country, and a nationwide team of experts, means theres no problem too big or too unique to solve together. Model 1 is the blueprint for creative commercial vehicle solutions. See why at model1.com.
Bienvenido a Citibanamex. Un espacio en donde cada paso cuenta para iniciar una nueva relación con tu dinero y en donde impulsamos a la transformación de nuestra comunidad y colaboradores. Conoce la información financiera más importante.
High to Low Voltage has made a name for itself sourcing electrical solutions for projects of all sizes, from smaller companies to large-scale data centers with enormous energy demands. Our expert sales team knows how to find the perfect equipment regardless of your electrical needs. High to Low Voltage. A business born out of a love of electrical equipment and necessity! Weve been problem-solving urgent electrical equipment needs for over 20 years, eager to put that experience to work for you in the moments that you need it most.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.